Saal, Germany

Christian Biberger

This inventor holds 2 USPTO granted patents. Top assignee: Schering Aktiengesellschaft. Active years: 2000-2003.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2000-2003

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Christian Biberger: Innovator in Pharmaceutical Chemistry

Introduction

Christian Biberger is a notable inventor based in Saal, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of antiestrogenic agents. With a total of 2 patents to his name, Biberger's work is recognized for its potential impact on medical treatments.

Latest Patents

Biberger's latest patents focus on the use of 2-phenylindoles as antiestrogenic pharmaceutical agents. These patents describe the compounds themselves, as well as the processes for synthesizing them. Additionally, they detail pharmaceutical preparations that incorporate these compounds and methods for utilizing them as effective pharmaceutical agents.

Career Highlights

Christian Biberger is currently employed at Schering Aktiengesellschaft, a prominent company in the pharmaceutical industry. His work there has allowed him to explore innovative solutions in drug development and contribute to advancements in medical science.

Collaborations

Throughout his career, Biberger has collaborated with esteemed colleagues such as Erwin Von Angerer and Martin Schneider. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the field.

Conclusion

Christian Biberger's contributions to pharmaceutical chemistry, particularly through his patents on 2-phenylindoles, highlight his role as an innovator in the industry. His work continues to pave the way for advancements in medical treatments and showcases the importance of collaboration in scientific research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…